...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell biology international. >Vector-based miR-15a/16-1 plasmid inhibits colon cancer growth in vivo
【24h】

Vector-based miR-15a/16-1 plasmid inhibits colon cancer growth in vivo

机译：基于载体的miR-15a / 16-1质粒在体内抑制结肠癌的生长

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

miR-15 (microRNA 15) and miR-16 are frequently deleted or down-regulated in many cancer cell lines and various tumour tissues, suggesting that miR-15a/16-1 plays important roles in tumour progression and might be a method for cancer treatment. We have developed a vector-based plasmid to explore the anti-tumour efficacy of miR-15a/16-1 in colon cancer in vivo. It is proposed that miR-15a and miR-16-1 target cyclin B1 (CCNB1), which associates with several tumorigenic features such as survival and proliferation. The levels of miR-15a and miR-16-1 in colon cancer cells were inversely correlated with CCNB1 expression, and there was consensus between miR-15a/16-1 and CCNB1 mRNA sequences by analysing homology. Vector-based miR-15a/16-1 expression plasmid was constructed and transfected into HCT 116 and SW620 colon cancer cells in vitro. The effects produced on cell viability and angiogenesis were analysed using flow cytometric analysis, colony formation analysis and tube formation analysis. CCNB1 expression down-regulation was checked by Western blotting. Systemic delivery of miR-15a/16-1 plasmids encapsulated in cationic liposome led to a significant inhibition of subcutaneous tumour growth and angiogenesis in tumour tissues, whereas no effects were observed with liposome carrying the non-specific plasmid. In summary, miR-15a/16-1 has been applied in colon cancer treatment in vivo, and resulted in effective colon tumour xenografts growth arrest and angiogenesis decrease. These findings suggest that systemic delivery of vector-based miR-15a/16-1 expression plasmid can be an approach to colon cancer therapy.
机译：在许多癌细胞系和各种肿瘤组织中，miR-15（microRNA 15）和miR-16经常被删除或下调，这表明miR-15a / 16-1在肿瘤进展中起着重要作用，可能是癌症的一种治疗方法治疗。我们已经开发了一种基于载体的质粒，以探索miR-15a / 16-1在体内结肠癌中的抗肿瘤功效。有人提出miR-15a和miR-16-1靶向细胞周期蛋白B1（CCNB1），这与几种致瘤功能有关，例如存活和增殖。通过分析同源性，结肠癌细胞中的miR-15a和miR-16-1的水平与CCNB1表达呈负相关，并且miR-15a / 16-1和CCNB1 mRNA序列之间存在共识。构建了基于载体的miR-15a / 16-1表达质粒，并在体外将其转染到HCT 116和SW620结肠癌细胞中。使用流式细胞仪分析，集落形成分析和管形成分析来分析对细胞活力和血管生成产生的影响。通过蛋白质印迹检查CCNB1表达下调。包裹在阳离子脂质体中的miR-15a / 16-1质粒的系统性递送可显着抑制肿瘤组织中皮下肿瘤的生长和血管生成，而携带非特异性质粒的脂质体则未观察到任何作用。总之，miR-15a / 16-1已用于体内结肠癌治疗，并导致有效的结肠肿瘤异种移植物生长停滞和血管生成减少。这些发现表明，基于载体的miR-15a / 16-1表达质粒的全身递送可以是结肠癌治疗的一种方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号